Prescription Abuse and Diversion by Secondary Students

处方药的非医疗使用和转移在青少年中是一个日益严重的问题。2002年，青少年非医疗处方滥用的终生流行率报告为13.7%，其中11.2%报告非医疗止痛药的使用。尽管目前青少年滥用处方的流行率相对较高，但这种形式的药物滥用在研究文献中受到的关注相对较少。此R03申请，处方滥用和转移中学生的主要目的是促进我们对非医疗使用和转移处方药的理解，横断面样本为居住在大都会一个学区的7到12年级学生 底特律。四类处方药(如兴奋剂、止痛药、镇静剂和睡眠)将是此次调查的重点，因为目前的研究表明，这些药物具有滥用潜力，青少年经常被开这些药物用于合法的医疗条件，增加了这些药物被转用的可能性。为了达到研究目标，将对报告非医疗用途或转移用途的学生进行描述，并描述他们的药物使用行为；还将描述学生的亚群(性别、种族等)。非医疗使用和转移处方药的相关性将与以前的处方、物质使用和非医疗使用处方的动机相关联。我们的长期目标是制定和评估一项具体的预防计划，以减少 使用R01机制的处方滥用和转移。

The nonmedical use and diversion of prescription drugs is an increasing problem among adolescents. In 2002, lifetime prevalence rates for adolescents' nonmedical prescription abuse was reported at 13.7% overall, with 11.2% reporting the nonmedical use of pain relievers. Despite the current and relatively high prevalence of prescription abuse by adolescents, this form of drug abuse receives relatively scant attention in the research literature. The primary purpose of this R03 application, Prescription Abuse and Diversion by Secondary Students is to advance our understanding of the nonmedical use and diversion of prescription drugs in a cross-sectional sample of 7th through 12th graders residing in one school district in metropolitan Detroit. Four categories of prescription drugs (e.g. stimulant, pain, sedative and sleep) will be the focus of this inquiry because current research suggests these medications have abuse potential and adolescents often are prescribed these drugs for legitimate medical conditions, increasing the likelihood that these medications will be diverted. To meet the study aims, students who report nonmedical use or diversion will be characterized and their drug use behaviors described; subgroups of students (gender, racial, etc) will be described as well. The correlates of the nonmedical use and diversion of prescription drugs will be examined in relation to previous prescriptions, substance use, and motivations to use prescriptions nonmedically. Our long term objective is to develop and evaluate a specific prevention program to reduce prescription abuse and diversion using an R01 mechanism.